WHAT IS THE MOST COST-EFFECTIVE POSITION OF VEDOLIZUMAB IN THE CURRENT TREATMENT ALGORITHM OF ULCERATIVE COLITIS?

被引：0
|
作者：
Scott, Frank I.
Shah, Yash
Lewis, James D.
机构：
来源：
GASTROENTEROLOGY | 2018年 / 154卷 / 01期
关键词：
D O I：
10.1053/j.gastro.2017.11.178
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
21
引用
收藏
页码：S66 / S67
页数：3
相关论文
共 50 条
  • [1] WHAT IS THE MOST COST-EFFECTIVE POSITION OF VEDOLIZUMAB IN THE CURRENT TREATMENT ALGORITHM OF ULCERATIVE COLITIS?
    Scott, Frank I.
    Shah, Yash
    Lewis, James D.
    [J]. INFLAMMATORY BOWEL DISEASES, 2018, 24 : S46 - S46
  • [2] What Is the Most Cost-Effective Position of Vedolizumab in Treatment Algorithms of Ulcerative Colitis From a Population Management Perspective?
    Scott, Frank I.
    Luo, Michelle
    Shah, Yash
    Lasch, Karen
    Lewis, James D.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S359 - S360
  • [3] Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis
    Scott, Frank I.
    Luo, Michelle
    Shah, Yash
    Lasch, Karen
    Vajravelu, Ravy K.
    Mamtani, Ronac
    Fennimore, Blair
    Gerich, Mark E.
    Lewis, James D.
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 (05): : 575 - 587
  • [4] Treatment cost of ulcerative colitis is apheresis with Adacolumn® cost-effective?
    Panes, J.
    Guilera, M.
    Ginard, D.
    Hinojosa, J.
    Gonzalez-Carro, P.
    Gonzalez-Lara, V.
    Varea, V.
    Domenech, E.
    Badia, X.
    [J]. DIGESTIVE AND LIVER DISEASE, 2007, 39 (07) : 617 - 625
  • [5] Current position on Vedolizumab for ulcerative colitis and Crohn's disease
    Schreiber, S.
    Dignass, A. U.
    Hartmann, H.
    Kruis, W.
    Rogler, G.
    Siegmund, B.
    Stallmach, A.
    Witte, C.
    Bokemeyer, B.
    [J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2015, 53 (06): : 591 - 602
  • [6] Determining the Optimal Position for Vedolizumab in the Current Treatment Paradigm for Ulcerative Colitis: A Markov Model
    Scott, Frank I.
    Shah, Yash
    Lasch, Karen
    Luo, Michelle
    Lewis, James
    [J]. GASTROENTEROLOGY, 2016, 150 (04) : S104 - S104
  • [7] Determining the Optimal Position For Vedolizumab In The Current Treatment Paradigm For Ulcerative Colitis: A Markov Model
    Scott, Frank I.
    Shah, Yash
    Lasch, Karen
    Luo, Michelle
    Lewis, James D.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 516 - 517
  • [8] Vedolizumab for the treatment of ulcerative colitis
    Stallmach, Andreas
    Schmidt, Carsten
    Teich, Niels
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 10 (02) : 165 - 175
  • [9] Vedolizumab for the treatment of ulcerative colitis
    Shahidi, Neal
    Bressler, Brian
    Panaccione, Remo
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (01) : 129 - 135
  • [10] Vedolizumab for the treatment of ulcerative colitis
    Rietdijk, Svend T.
    D'Haens, Geert R.
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (04) : 423 - 430
12345